N
KPTI icon

Nuveen’s Karyopharm Therapeutics KPTI Stock Holding History

Nuveen’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-32,824
Closed -$743K – 3379
2024
Q1 		$743K Buy
32,824
+2,537
+8% +$44.5K ﹤0.01% 2824
2023
Q4 		$393K Buy
30,287
+127
+0.4% +$1.71K ﹤0.01% 3080
2023
Q3 		$606K Sell
30,160
-742
-2% -$16.7K ﹤0.01% 2779
2023
Q2 		$830K Sell
30,902
-87,667
-74% -$3.78M ﹤0.01% 2734
2023
Q1 		$6.92M Buy
118,569
+12,322
+12% +$608K ﹤0.01% 1703
2022
Q4 		$5.42M Sell
106,247
-25,156
-19% -$1.74M ﹤0.01% 1863
2022
Q3 		$10.8M Buy
131,403
+5,044
+4% +$377K ﹤0.01% 1430
2022
Q2 		$8.55M Buy
126,359
+5,089
+4% +$467K ﹤0.01% 1616
2022
Q1 		$11.9M Buy
121,270
+42,316
+54% +$5.27M ﹤0.01% 1540
2021
Q4 		$6.71M Buy
78,954
+4,353
+6% +$434K ﹤0.01% 1933
2021
Q3 		$6.79M Sell
74,601
-1,127
-1% -$117K ﹤0.01% 2050
2021
Q2 		$11.7M Buy
75,728
+13,757
+22% +$2M ﹤0.01% 1764
2021
Q1 		$9.78M Sell
61,971
-6,535
-10% -$1.38M ﹤0.01% 1816
2020
Q4 		$15.9M Sell
68,506
-1,643
-2% -$381K 0.01% 1393
2020
Q3 		$15.4M Buy
70,149
+41,966
+149% +$10.3M 0.01% 1225
2020
Q2 		$8.01M Buy
28,183
+9,235
+49% +$2.73M ﹤0.01% 1637
2020
Q1 		$5.46M Sell
18,948
-11,875
-39% -$3.28M ﹤0.01% 1664
2019
Q4 		$8.86M Buy
30,823
+4,255
+16% +$923K ﹤0.01% 1657
2019
Q3 		$3.83M Buy
26,568
+854
+3% +$116K ﹤0.01% 2102
2019
Q2 		$2.31M Buy
+25,714
New +$2.06M ﹤0.01% 2369
2014
Q3 		– Sell
-725
Closed -$506K – 1616
2014
Q2 		$506K Buy
725
+30
+4% +$14K ﹤0.01% 1365
2014
Q1 		$322K Sell
695
-542
-44% -$275K ﹤0.01% 1417
2013
Q4 		$425K Buy
+1,237
New +$342K ﹤0.01% 1351

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen's KPTI Position: Q2 2024 in Review

Nuveen sold out of Karyopharm Therapeutics (KPTI) in Q2 2024, closing a stake of 32,824 shares — an estimated $743K sold.

Nuveen first reported a position in KPTI in Q4 2013 and held it in 23 quarters. The position peaked at $15.9M in Q4 2020. 114 funds tracked by Wall St. Rank hold KPTI as of Q2 2024.

  • Nuveen reported no remaining Karyopharm Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Nuveen sold 32,824 Karyopharm Therapeutics shares in Q2 2024, an estimated $743K.
  • Nuveen first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 23 quarters.
  • Nuveen's Karyopharm Therapeutics position peaked at $15.9M in Q4 2020.
  • 114 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2024.

Based on Nuveen's 13F filing for Q2 2024, filed 9 Aug 2024.